Does Amerigroup Cover Eliquis?

What Is Eliquis and Why Does Coverage Matter?

Eliquis (apixaban) is a direct oral anticoagulant (DOAC) approved by the FDA in 2012 for reducing stroke risk in nonvalvular atrial fibrillation and for treating deep vein thrombosis (DVT) and pulmonary embolism (PE). Without insurance, a 60-tablet supply of Eliquis 5 mg costs between $550 and $620 at most U.S. retail pharmacies, making coverage questions clinically and financially urgent for Medicaid enrollees.

The ARISTOTLE trial (N=18,201) demonstrated that apixaban reduced the rate of stroke or systemic embolism by 21% compared with warfarin (1.27% vs. 1.60% per year; P<0.001), with a 31% reduction in major bleeding [1]. Those numbers gave clinicians a compelling reason to prescribe it over warfarin for many patients, yet the drug's brand-only status keeps it on higher formulary tiers across nearly every state Medicaid program.

Amerigroup, now operating under the Elevance Health (formerly Anthem) umbrella, contracts with state Medicaid agencies to manage benefits for low-income enrollees. Because each state negotiates its own preferred drug list (PDL) with Amerigroup, a member in Georgia may face different prior authorization (PA) requirements than a member in Nevada or Maryland. That state-by-state variability is the single biggest reason why a yes-or-no answer about Eliquis coverage does not hold across all Amerigroup plans.

How Amerigroup Formularies Work

Each Amerigroup state plan publishes a formulary, also called a drug list or PDL, that assigns covered drugs to tiers. Tier placement drives the copay and determines whether a PA is needed.

Medicaid programs are required under federal law (42 CFR 438.3) to cover all medically necessary services, but states retain wide latitude to manage how they cover specific drugs and what utilization management tools they apply [2]. Amerigroup complies with its state contract while also applying its own clinical policy criteria. The result is a layered system: the state PDL sets the floor, and Amerigroup's clinical policies add conditions on top.

For Eliquis specifically, most state Medicaid PDLs place it in a non-preferred brand tier. On a non-preferred tier, coverage often requires the prescriber to demonstrate that a preferred alternative has failed, is contraindicated, or is clinically inappropriate. Preferred alternatives on virtually every state Medicaid PDL include warfarin and, in many states, at least one other DOAC such as rivaroxaban or dabigatran at a lower tier.

One useful benchmark: the Medicaid Drug Rebate Program (MDRP) compels manufacturers like Bristol-Myers Squibb to pay statutory rebates when drugs are covered, which sometimes leads states to negotiate supplemental rebate agreements that move a drug to a preferred tier mid-year [3]. Checking the current formulary, not a version from six months ago, is the only reliable approach.

Prior Authorization Requirements for Eliquis on Amerigroup

Prior authorization is almost universally required before Amerigroup will dispense Eliquis to a member for the first time. The PA process protects against off-label use, confirms the diagnosis, and often enforces step therapy.

The following framework reflects common Amerigroup PA criteria for Eliquis across multiple states. Specific criteria vary by state and plan year, so confirm with Amerigroup directly.

Typical Amerigroup PA criteria for Eliquis:

1. Diagnosis confirmation. The prescriber must document nonvalvular atrial fibrillation, DVT, PE, or another FDA-approved indication. ICD-10 codes are usually required on the PA request.

2. Step therapy. Most plans require documentation of a 30 to 90-day trial of warfarin or another preferred anticoagulant, unless the patient has a contraindication. Contraindications accepted by most plans include labile INR on warfarin (defined as time in therapeutic range <60% over 6 months), documented intolerance, or a drug-drug interaction that cannot be managed.

3. Renal function. Because apixaban dosing adjusts for renal impairment, some plans request a recent serum creatinine or estimated GFR to verify the prescribed dose is appropriate. The FDA label recommends 2.5 mg twice daily if the patient has at least two of the following: serum creatinine ≥1.5 mg/dL, age ≥80 years, or body weight ≤60 kg [4].

4. Prescriber type. Some Amerigroup plans limit initial PA approval to cardiologists, hematologists, or other specialists, although primary care physicians may request PA with supporting clinical documentation.

5. Authorization duration. Initial approvals typically run 6 to 12 months, after which reauthorization is required.

Submitting an incomplete PA request is the most common reason for delay or denial. The prescriber's office should include the diagnosis code, relevant lab values, documentation of the step therapy trial or contraindication, and the clinical rationale in a single submission to avoid back-and-forth with the plan.

How to Check Your Specific Amerigroup Plan Coverage

There are four reliable methods to confirm whether Eliquis is covered under your individual plan:

1. Amerigroup's online formulary tool. Log into the member portal at amerigroup.com and use the drug search function. Enter "apixaban" or "Eliquis," select your plan, and review the tier, copay, and any utilization management flags. Formularies update on January 1 each plan year and may change mid-year with 60-day advance notice to members.

2. Member services by phone. Call the number on the back of your Amerigroup insurance card. Ask the representative to confirm whether Eliquis is on the formulary, what tier it occupies, whether PA is required, and what the current step therapy policy is. Document the call date, representative name, and reference number.

3. Your prescriber's office. Physicians and their staff perform PA requests routinely. Cardiologists and electrophysiologists who manage atrial fibrillation patients are familiar with DOAC coverage barriers and can initiate an electronic PA through the CoverMyMeds platform or directly through Amerigroup's provider portal.

4. State Medicaid PDL. Each state Medicaid agency publishes its own PDL, which Amerigroup is contractually bound to follow. Searching "[your state] Medicaid preferred drug list 2025" will show whether Eliquis has preferred or non-preferred status in your state.

What Happens If Amerigroup Denies Coverage?

A denial is not the end of the road. Federal Medicaid managed care regulations under 42 CFR 438.400 through 438.424 give enrollees the right to appeal any adverse coverage decision [5]. The process moves in three stages.

Internal appeal. File within 60 days of the denial notice. For urgent situations (for example, a patient being discharged from the hospital on Eliquis for a new PE diagnosis), the plan must issue a decision within 72 hours. Standard appeals must be resolved within 30 days under CMS Medicaid managed care rules.

State fair hearing. If the internal appeal is denied, you may request a state fair hearing through your state's Medicaid agency. At this stage, an independent administrative law judge reviews whether the plan's decision complied with state and federal law. If you request a hearing within 10 days of the denial and before the coverage end date, you may be entitled to continuation of benefits while the hearing proceeds.

External review (in applicable states). Some states allow an additional layer of independent external review by a third-party organization, adding another avenue before accepting a denial as final.

The American Heart Association's 2023 Atrial Fibrillation Guideline states: "In patients with AF and CHA2DS2-VASc score ≥2 in men or ≥3 in women, oral anticoagulation is recommended to reduce the risk of stroke and systemic thromboembolism" [6]. That language, combined with ARISTOTLE outcome data showing a 31% reduction in major bleeding with apixaban versus warfarin, gives prescribers strong clinical grounds to argue medical necessity during an appeal.

Preferred Alternatives Amerigroup Typically Covers Without Prior Authorization

If prior authorization is denied or the process is taking too long for a clinically urgent patient, several anticoagulants are available at preferred tiers on most Amerigroup Medicaid plans.

Warfarin (generic coumadin). Warfarin remains Tier 1 on virtually every state Medicaid PDL because generic versions cost under $10 per month. The RE-LY trial (N=18,113) and ARISTOTLE trial both used warfarin as the comparator, confirming its efficacy for stroke prevention in atrial fibrillation [1][7]. The drawback is narrow therapeutic index, requiring frequent INR monitoring, which some patients find burdensome.

Rivaroxaban (Xarelto). Some Amerigroup state plans have negotiated supplemental rebates that place rivaroxaban on a preferred DOAC tier. The ROCKET AF trial (N=14,264) showed rivaroxaban was non-inferior to warfarin for stroke prevention (1.7% vs. 2.2% per year; P<0.001 for non-inferiority) [8]. If your plan prefers rivaroxaban over apixaban, your cardiologist may consider switching, particularly since both share the Factor Xa mechanism.

Dabigatran (Pradaxa). The RE-LY trial (N=18,113) showed dabigatran 150 mg twice daily reduced stroke by 34% compared with warfarin [7]. Dabigatran requires dose adjustment for renal function (avoid if CrCl <15 mL/min) and is not ideal for patients with significant GI intolerance.

The clinical choice among DOACs involves patient-specific factors including renal function, body weight, bleeding history, pill burden, and cost. Switching solely for formulary reasons should happen with the prescriber's explicit guidance.

Manufacturer and Third-Party Financial Assistance Programs

Even when Amerigroup denies Eliquis coverage, patients may access the drug through other channels.

Bristol-Myers Squibb Patient Assistance Foundation. Uninsured or underinsured patients who meet income criteria (generally at or below 200 to 400% of the federal poverty level, depending on program) may receive Eliquis at no cost through the BMS Patient Assistance Foundation. Applications are submitted through the NeedyMeds database or directly via the BMS website [9].

Eliquis Co-Pay Card. The BMS/Pfizer co-pay card program offers savings of up to $10 per month for commercially insured patients. Medicaid beneficiaries are generally excluded from manufacturer co-pay card programs under federal anti-kickback statutes, so this option usually does not apply to Amerigroup Medicaid members. It may apply to Amerigroup Medicare Advantage members.

State Pharmaceutical Assistance Programs (SPAPs). Several states operate their own programs that supplement Medicare or Medicaid drug coverage. Check with your state health department or the Medicare SPAP database to see if your state offers additional help.

Rx outreach and other patient assistance nonprofits. Organizations such as RxAssist, NeedyMeds, and the Partnership for Prescription Assistance maintain searchable databases of assistance programs by drug name and income level [9].

Amerigroup Medicare Advantage vs. Medicaid: Different Coverage Rules

Amerigroup offers both Medicaid managed care and Medicare Advantage plans in select states, and coverage rules differ substantially between the two.

On an Amerigroup Medicare Advantage Prescription Drug (MA-PD) plan, Eliquis is subject to Medicare Part D formulary rules rather than state Medicaid PDL rules. Under CMS guidance, all Medicare Part D plans are required to cover at least two drugs in each drug category and class, and anticoagulants are a protected class under the CMS Part D formulary guidelines. That protected-class status means Medicare Advantage plans may cover Eliquis with fewer utilization management barriers than Medicaid plans, though a PA is still possible [10].

The Centers for Medicare and Medicaid Services (CMS) stated in its 2024 Medicare Part D Final Rule: "Plans must cover all or substantially all drugs in six protected classes," which includes anticoagulants, immunosuppressants, antidepressants, antipsychotics, anticonvulsants, and antiretrovirals [10]. That regulatory language gives Medicare Advantage enrollees a stronger legal basis for coverage than Medicaid enrollees in most scenarios.

If you are dually eligible (both Medicaid and Medicare), your drug coverage typically flows through Medicare Part D first, making the Medicare protected-class rules the relevant standard rather than the state Medicaid PDL.

Clinical Considerations That Strengthen a Prior Authorization Request

A well-constructed PA request from the prescriber dramatically improves the odds of approval. Several clinical findings, if documented in the medical record, provide the clearest justification.

Labile INR history is the strongest argument for DOAC coverage on most Amerigroup plans. A time in therapeutic range (TTR) below 60% over at least 90 days of warfarin therapy is widely accepted as evidence of poor warfarin control. The SAMe-TT2R2 score, which predicts likelihood of poor TTR on warfarin, assigns 2 points for non-white race and for treatment with interacting medications, and 1 point each for female sex, age <60, medical history of two or more comorbidities, and current smoker [11]. A score of 2 or higher predicts poor warfarin control and is increasingly cited in PA narratives.

Renal function data matters. At a CrCl between 15 and 29 mL/min, apixaban's pharmacokinetic profile may be more predictable than warfarin's, though the evidence base is extrapolated from subgroup analyses rather than dedicated trials. Documenting the exact CrCl value and referencing the FDA label's dose-adjustment criteria makes the PA more defensible.

Drug interaction lists help. Patients on azole antifungals, certain HIV antiretrovirals, or rifampin face P-glycoprotein and CYP3A4 interactions with warfarin and with some DOACs. If the patient's medication list includes a strong P-gp inhibitor that would require apixaban dose modification, noting this in the PA submission demonstrates that the prescriber has reviewed the full clinical picture.

The American College of Cardiology's 2023 AF guideline update recommends apixaban or rivaroxaban as preferred DOACs when renal function permits, citing the combination of efficacy and bleeding data from ARISTOTLE and ROCKET AF [6]. Quoting this guideline recommendation by name in the PA letter gives the plan's pharmacy team a specific clinical standard to weigh.

Timing and Practical Tips for Amerigroup Members

Several practical steps reduce out-of-pocket exposure while the PA process moves forward.

Most hospital discharge pharmacies and outpatient cardiologists can provide a short-term sample supply of Eliquis through the BMS sample program, covering 7 to 14 days while PA is under review. Ask the prescriber's office to request samples directly from their BMS pharmaceutical representative.

The PA submission clock starts when Amerigroup receives a complete request, not when the prescriber's office submits it. A follow-up call to Amerigroup's PA department 48 hours after submission confirms receipt and identifies any missing documents before the review period begins.

For patients with atrial fibrillation being discharged from the hospital, the CHA2DS2-VASc score guides urgency. A score of 4 or higher (indicating an annual stroke risk above 4%) makes a 72-hour urgent PA request medically justifiable rather than waiting for the standard 30-day track.

Keeping a copy of every PA submission, every denial letter, and every appeal filing creates the paper trail needed if the case eventually reaches a state fair hearing. Date stamps on faxed documents and portal confirmation numbers carry the same weight as certified mail in most administrative proceedings.